Diphosphonates remain among the most common drug treatments for osteoporosis. Recent evidence has implicated diphosphonate therapy, specifically, alendronate, with low-energy fractures of the subtrochanteric region of the femur. The general conclusion is that prolonged suppression of bone remodelling with alendronate may be associated with a new form of insufficiency fracture of the femur.

Three case reports of patients with alendronate related insufficiency are discussed here with their treatment modalities and lessons learnt. One of the three patients had bilateral subtrochanteric stress fracture. A comprehensive review of the literature is presented with the best evidence for investigating, treating and preventing these fractures

Our experience in Launceston has increased awareness amongst the local medical community regarding the long term use of Diphosphnates and the fractures they may cause. Changes to our practice have included: Increased suspicion of patients with hip pain on diphosphonate therapy, imaging the contralateral femur to rule out stress fractures, reassuring GP's and Patients that benefits of Diphosphonate therapy far outweigh the potential risks.

There are many unresolved questions about the prolonged use of diphosphonates, but there is sufficient evidence to show subtrochanteric stress fractures do occur. We, as Orthopaedic Surgeons, must be able to recognize this new entity and educate our medical colleagues appropriately.

This paper discussed the challenges to provide advanced surgical training in orthopaedics, the inter-relationship between trainers, trainees, the AOA and the College. It looks at the factors that are involved in each level of training, some of the new initiatives that are being undertaken and the medicolegal issues regarding training of the modern generation of Orthopaedic trainees. It also discusses the pitfalls in process, that are present for all those involved in the training.

Antibiotics are frequently administered prophylactically in spinal procedures to reduce the risk of disc space infection. There is still controversy, however, over which antibiotics are able to penetrate the intervertebral disc effectively and whether the charges on the antibiotics are important in determining their ability to diffuse into the negatively charged intervertebral disc.

In a prospective randomised double blind clinical study, we examined the penetration of two commonly used antibiotics, cefuroxime (negatively charged) and gentamicin (positively charged), into the intervertebral discs. Twenty patients, randomised into two separate groups, received either 1.5g cefuroxime or 5 mg/kg gentamicin prophylactically two hours before their intervertebral discs removed. A blood specimen, from which serum antibiotic levels were determined, was obtained simultaneously with each discectomy.

Clinical therapeutic levels of antibiotic were detectable in the intervertebral discs of all the ten patients who received gentamicin. Only two of the ten patients (20%) who received cefuroxime had quantifiable level of antibiotic in their discs even though serum levels of cefuroxime were at therapeutic levels in all ten patients. Our results showed that cefuroxime does not diffuse into human intervertebral discs as readily as gentamicin and suggest that the charge due to ionisable groups on the antibiotics is important in determining the penetration of antibiotics. We therefore recommend the use of gentamicin in a single prophylactic dose for all spinal procedures to reduce the incidence of post-operative discitis.